3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Biphenotypic, Acute
1
Leukemia
1
Interventions
Cyclophosphamide
17
Cytarabine
11
venetoclax
9
fludarabine
9
Mycophenolic Acid
8
Busulfan
7
fludarabine phosphate
6
Whole-Body Irradiation
6
ruxolitinib
5
Tacrolimus
5
Methotrexate
5
Daunorubicin
5
Cyclosporine
5
Azacitidine
5
ponatinib
4
Vincristine
4
Rituximab
4
Peripheral Blood Stem Cell Transplantation
4
Etoposide
4
Dexamethasone
4
blinatumomab
3
asciminib
3
Prednisone
3
Mercaptopurine
3
Inotuzumab Ozogamicin
3
Doxorubicin
3
revumenib
2
quizartinib
2
pegfilgrastim
2
pegaspargase
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia
×
Cobicistat
×
90 days
×
Clear all
NCT04065399
2026-03-18
AUGMENT-101
Syndax Pharmaceuticals
Phase 1/2
Recruiting
447 enrolled
2 FDA